247 related articles for article (PubMed ID: 15182761)
1. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
Simůnek T; Klimtová I; Kaplanová J; Mazurová Y; Adamcová M; Sterba M; Hrdina R; Gersl V
Eur J Heart Fail; 2004 Jun; 6(4):377-87. PubMed ID: 15182761
[TBL] [Abstract][Full Text] [Related]
2. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
[TBL] [Abstract][Full Text] [Related]
4. Experimental animal model for anthracycline-induced heart failure.
Perik PJ; van den Berg MP; de Vries EG; van Veldhuisen DJ
Eur J Heart Fail; 2004 Jun; 6(4):375-6. PubMed ID: 15182760
[No Abstract] [Full Text] [Related]
5. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity.
Sterba M; Popelová O; Simunek T; Mazurová Y; Potácová A; Adamcová M; Kaiserová H; Ponka P; Gersl V
J Pharmacol Exp Ther; 2006 Dec; 319(3):1336-47. PubMed ID: 17003229
[TBL] [Abstract][Full Text] [Related]
6. Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits.
Simůnek T; Sterba M; Holecková M; Kaplanová J; Klimtová I; Adamcová M; Gersl V; Hrdina R
Biometals; 2005 Apr; 18(2):163-9. PubMed ID: 15954742
[TBL] [Abstract][Full Text] [Related]
7. Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits.
Simůnek T; Klimtová I; Kaplanová J; Sterba M; Mazurová Y; Adamcová M; Hrdina R; Gersl V; Ponka P
Pharmacol Res; 2005 Mar; 51(3):223-31. PubMed ID: 15661572
[TBL] [Abstract][Full Text] [Related]
8. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH).
Sterba M; Popelová O; Simůnek T; Mazurová Y; Potácová A; Adamcová M; Guncová I; Kaiserová H; Palicka V; Ponka P; Gersl V
Toxicology; 2007 Jun; 235(3):150-66. PubMed ID: 17459556
[TBL] [Abstract][Full Text] [Related]
9. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.
Kollárová-Brázdová P; Lenčová-Popelová O; Karabanovich G; Kocúrová-Lengvarská J; Kubeš J; Váňová N; Mazurová Y; Adamcová M; Jirkovská A; Holečková M; Šimůnek T; Štěrbová-Kovaříková P; Roh J; Štěrba M
Clin Sci (Lond); 2021 Aug; 135(15):1897-1914. PubMed ID: 34318878
[TBL] [Abstract][Full Text] [Related]
10. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
11. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M
Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693
[TBL] [Abstract][Full Text] [Related]
12. [Effects of new antineoplastic agents (dimethoxybenflurone and Oracin) on the cardiovascular system and other parameters in the rabbit in vivo].
Machácková J; Gersl V; Adamcová M; Mazurová Y; Hrdina R; Mĕlka M; Nobilis M
Acta Medica (Hradec Kralove) Suppl; 2000; 43(2):119-38. PubMed ID: 11413675
[TBL] [Abstract][Full Text] [Related]
13. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
14. [Protective effect of dexrazoxane on cardiotoxicity in breast cancer patients who received anthracycline-containing chemotherapy].
Wang P; Zhang S; Zhang XB; Li WJ; Hao XM; Zhang J
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):135-9. PubMed ID: 23714670
[TBL] [Abstract][Full Text] [Related]
15. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
[TBL] [Abstract][Full Text] [Related]
16. Protein profiling in daunorubicin-induced cardiomyopathy.
Adamcová M; Pelouch V; Gersl V; Kaplanová J; Mazurová Y; Simůnek T; Klimtová I; Hrdina R
Gen Physiol Biophys; 2003 Sep; 22(3):411-9. PubMed ID: 14986890
[TBL] [Abstract][Full Text] [Related]
17. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
19. [Cardiotoxicity of conservative treatment of solid tumors].
Sivak LA; Askol'skiĭ AV; Lial'kin SA; Klimanov MIu; Maĭdanevich NN; Kasap NV
Lik Sprava; 2011; (3-4):51-9. PubMed ID: 22416364
[TBL] [Abstract][Full Text] [Related]
20. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
